AGGRASTAT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Cyprus, Estonia, Finland, Hong Kong SAR China, Israel, Lithuania, Malta, Netherlands, Singapore, UK.

Active ingredients

The drug AGGRASTAT contains one active pharmaceutical ingredient (API):

1	Tirofiban hydrochloride monohydrate UNII 6H925F8O5J - TIROFIBAN HYDROCHLORIDE
	Tirofiban is a non-peptidal antagonist of the GP IIb/IIIa receptor, an important platelet surface receptor involved in platelet aggregation. Tirofiban prevents fibrinogen from binding to the GP IIb/IIIa receptor, thus blocking platelet aggregation.
	Read more about Tirofiban

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AC17	Tirofiban	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC17

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8350L
CA	Health Products and Food Branch	02240706
EE	Ravimiamet	1033962
FI	Lääkealan turvallisuus- ja kehittämiskeskus	003088, 004450, 517391
GB	Medicines & Healthcare Products Regulatory Agency	76035, 76039
HK	Department of Health Drug Office	44541
IL	מִשְׂרַד הַבְּרִיאוּת	7349
LT	Valstybinė vaistų kontrolės tarnyba	1013670
MT	Medicines Authority	AA565/86601, MA1311/00101
NL	Z-Index G-Standaard	14635054
NL	Z-Index G-Standaard, PRK	58742
SG	Health Sciences Authority	10931P
US	FDA, National Drug Code	25208-001, 25208-002